Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma

We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC). Patients with measurable disease received S-1 orally b.i.d. on days 1–14 and d...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Park, S R, Kim, H K, Kim, C G, Choi, I J, Lee, J S, Lee, J H, Ryu, K W, Kim, Y-W, Bae, J-M, Kim, N K
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2008
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361699/
https://ncbi.nlm.nih.gov/pubmed/18362939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604312
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak